MEDIA RELEASE

Kuala Lumpur / Singapore, 27 August 2026

IHH Healthcare delivers double-digit growth in Q2 2026

Diversified footprint, Group synergies and country-specific strategies drive strength

"We accelerated our strong growth momentum in Q2 2026 on higher patient volumes and more complex case mix. As a uniquely diversified, multinational network, IHH is able to navigate uncertainties through targeted strategies for each of our 10 countries, while ensuring Group-level synergies on cost, systems and operational excellence. We remain confident on reaching double-digit ROE by 2028."

-- Dr Prem Kumar Nair, Group Chief Executive Officer, IHH Healthcare

GROUP RESULTS – Q2 2026 FINANCIAL SUMMARY

	Reported Q2 2026 key metrics (YoY)		**Core**[1] Q2 2026 key metrics (YoY)	
Financials (RM)	***Q2 2026***	***YoY (%)***	***Q2 2026***	***YoY (%)***
Revenue	RM7.0b	**+12%**	RM6.9b	**+19%***
EBITDA	RM1.6b	**+19%**	RM1.6b	**+25%***
PATMI (ex EI)	RM569m	**+36%**	RM675m	**+30%**
PATMI	RM573m	**+29%**	RM674m	**+28%**

**On constant currency basis*

GROUP RESULTS – H1 2026 FINANCIAL SUMMARY

	Reported H1 2026 key metrics (YoY)		**Core**[1] H1 2026 key metrics (YoY)	
Financials (RM)	***H1 2026***	***YoY (%)***	***H1 2026***	***YoY (%)***
Revenue	RM13.6b	**+8%**	RM13.4b	**+17%***
EBITDA	RM3.0b	**+13%**	RM3.0b	**+21%***
PATMI (ex EI)	RM1.0b	**+22%**	RM1.2b	**+17%**
PATMI	RM1.1b	**+15%**	RM1.2b	**+16%**

**On constant currency basis*

[1] *Excluding effects of application of MFRS129 accounting*

Q2 2026: Double-digit growth in all key metrics on resilient, multinational portfolio

- **Core revenue** (on a constant currency basis) was up **19% (RM6.9b)** year-on-year (YoY) and **core PATMI (ex EI)** was up **30% (RM675m)** YoY. Higher inpatient and daycase volumes, with an increase in complex case mix contributed to growth.
- At a country level, **Malaysia, Türkiye & Europe, and India saw strong performances:**
  - Malaysia reported higher revenue intensity and inpatient admissions, while growing daycase volumes and revenue by double digits.
  - Türkiye & Europe continue to deliver broad-based growth, with strong local and foreign demand even with bed additions at Kartal, Kent and Bayindir hospitals.
  - India continues to benefit from Fortis Healthcare and Gleneagles India integration from their maintenance services agreement (MSA) as well as organic growth.
- **Singapore stayed on track for recovery in H2 2026** as guided:
  - Occupancy picked up from Q1 lows to 51% in Q2 with strong margins of 29%.
  - IHH SG continues to focus on driving higher volumes, launching new packages in the past quarter with leading insurers. More price-competitive packages are expected to launch in the coming months.
- **Reported revenue** was up 12% (RM7.0b) YoY; **reported PATMI** was up 29% (RM573m) YoY as **strength of Group's diversified portfolio** mitigated global volatilities despite the translation impact from a stronger Ringgit.

H1 2026: Strong core growth amid Ringgit strength

- **Core revenue** (on a constant currency basis) and **core PATMI (ex EI)** both grew **17%** YoY **(RM13.4b** and **RM1.2b** respectively**)** on continued operational strength across Malaysia, Türkiye & Europe and India.
- **Reported revenue** was up 8% (RM13.6b) YoY; **reported PATMI** was up 15% (RM1.1b) YoY.
- **Strong cash flow and robust balance sheet:** Cash balance of RM1.3b as at 30 June 2026; net gearing at 0.4 times on Group-wide operational strength with active cost discipline and prudent capital management.

GROUP OUTLOOK

- IHH is on a multi-year transformation journey to future-proof its business, accelerate growth and drive profitability; targeting double-digit return-on-equity (ROE) by 2028.
- Amid rising demand, IHH remains confident in its growth trajectory, underpinned by strong clinical capabilities. Its 2026 focus areas are:
    - **Malaysia**: Continue to grow daycase and medical tourism segments, strengthen payor partnerships and conduct brownfield expansion selectively.
    - **Singapore**: Strengthen payor partnerships, grow medical tourism from non-traditional markets, sustain quaternary excellence and optimise and scale network effects from presence across continuum.
    - **India**: Fortis and Gleneagles MSA will continue to drive scale and leverage from further integration; will also accelerate strategic brownfield expansion to meet demand.
    - **Türkiye & Europe**: Acibadem will focus on maintaining market leadership while staying capital-light and driving operational resilience.
- IHH also remains prudent on its capital management while navigating through global volatilities and uncertainties.

+++

ABOUT IHH HEALTHCARE ("IHH")

IHH is a leading multinational healthcare provider shaping the future of care. Driven by our aspiration to Care. For Good., we unite medical excellence and innovation, pushing boundaries through our trusted brands such as Acibadem, Gleneagles, Fortis, Island, Mount Elizabeth, Pantai, Parkway and Prince Court.

Across 10 countries, including Malaysia, Singapore, Türkiye, India and Greater China, our 76,000-strong team delivers world-class excellence every day, within and beyond our 190 healthcare facilities, including 89 hospitals. Our comprehensive services span the full healthcare continuum, from primary and ambulatory to quaternary care, complemented by diagnostics, imaging, rehabilitation, telehealth and home care.

In partnership with our stakeholders, IHH is advancing value-based care, building a sustainable healthcare ecosystem and creating meaningful impact, as we work towards our vision to become the world's most trusted healthcare services network.
www.ihhhealthcare.com

For more information or to speak to an IHH spokesperson, please contact:

Kelvin Chong
Investor Relations, IHH Healthcare
t. +65 9489 5357
e. kelvin.chong@ihhhealthcare.com

Jeremy Fong
Investor Relations, IHH Healthcare
t. +65 8127 3352
e. jeremy.fong@ihhhealthcare.com